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The canonical Wnt ⁄ b-catenin pathway plays an important role in different devel-
opmental processes through the regulation of stem cell functions. In the activa-
tion of the canonical Wnt ⁄ b-catenin pathway, b-catenin protein is imported into
the nucleus and activates transcription of target genes including cyclin D1 and c-
myc. Aberrant activation of the Wnt ⁄ b-catenin pathway contributes to carcino-
genesis and malignant behaviors, and Wnt signaling is essential for the mainte-
nance of cancer stem cells. The canonical Wnt ⁄ b-catenin pathway has been
investigated extensively as a target in cancer treatment and several specific inhib-
itors of this signaling pathway have been identified through high-throughput
screening. In this review, the significance of the canonical Wnt ⁄ b-catenin path-
way in hematological carcinogenesis and screening methods for specific inhibi-
tors are discussed.
W nt signaling plays important roles in developmentalprocesses and cell growth and differentiation. Three
Wnt signaling pathways have been characterized, including the
canonical Wnt ⁄b-catenin pathway. Signals of the canonical
Wnt ⁄b-catenin pathway are transduced through a member of
the Fz receptor family and the LRP5 ⁄6 co-receptor to the
b-catenin cascade. This pathway regulates cell proliferation
and developmental processes. The canonical Wnt ⁄b-catenin
pathway is aberrantly activated in cancers, and it has therefore
been investigated as a potential therapeutic target for the treat-
ment of cancer. The present review focuses on the role of the
canonical Wnt ⁄b-catenin pathway in hematological malignan-
cies and discusses the development of small molecule inhibi-
tors against this canonical pathway.
Canonical Wnt ⁄ b-catenin Pathway
The precise signal transduction of the canonical Wnt ⁄b-catenin
pathway has been described in several reviews.(1,2) b-Catenin
is a multifunctional protein that exists in different subcellular
components. A major membrane-bound form of b-catenin
interacts with E-cadherin and connects actin filaments through
a-catenin to form the cytoskeleton. Membrane-bound b-catenin
is released into the cytosol by tyrosine phosphorylation.
Cytosolic b-catenin acts as a downstream protein of the canon-
ical Wnt signaling pathway in stimulated cells. In the absence
of Wnt proteins, adenomatous polyposis coli, Axin, GSK3b,
and casein kinase 1a form the “b-catenin destruction
complex”. The phosphorylated b-catenin in the b-catenin
destruction complex is polyubiquitinated by b-transducin
repeat-containing protein, a component of a ubiquitin ligase
complex, targeting b-catenin for rapid degradation by the pro-
teasome. Consequently, the transcription of the downstream
genes involved in cell-cycle regulation, cell adhesion, and cel-
lular development are repressed. On the other hand, the bind-
ing of Wnt proteins to Fz receptors and LRP5 ⁄6 co-receptors
induces the phosphorylation of Disheveled and prevents
GSK3b-dependent phosphorylation of b-catenin. b-Catenin is
stabilized in cytoplasm and translocates into the nucleus,
where it interacts with TCF ⁄LEF, resulting in activation of the
transcription of target genes (Fig. 1).
Wnt ⁄ b-catenin Pathway in Hematological Malignancies
Hematopoiesis is a continuous process by which HSCs and
HPCs develop into mature hematopoietic cells. Many signaling
pathways involved in hematopoiesis have been characterized;
among these, the canonical Wnt signaling is essential for the
maintenance of HSCs.(3,4) Inhibition of GSK3b, which leads to
activation of b-catenin, promotes hematopoiesis. Short-term
pretreatment of human HSCs with a GSK3b inhibitor, 6-bromo-
indirubin 30-oxime, increased engraftment into immunodeficient
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mice.(5) The constitutively active form of b-catenin repro-
grammed lymphoid and myeloid progenitors to multipotent
HPCs.(6) Moreover, HSCs from mice lacking b-catenin are defi-
cient in their long-term maintenance.(7) However, mice express-
ing stabilized b-catenin in the hematopoietic system showed
expansion of HSCs with arrested differentiation, and led to
defects in hematopoietic reconstitution. Therefore, the Wnt path-
way plays an important role in fine-tuning the regulation of
hematopoiesis.(8,9)
The dysregulation of Wnt ⁄b-catenin signaling is associated
with the development of hematological malignancies. b-Cate-
nin is aberrantly expressed in patients with AML,(10,11) and
high expression of b-catenin is associated with poor prognosis
in AML.(12) Normal human CD34+ HPCs overexpress b-cate-
nin compared to mature cells, and b-catenin is downregulated
during myeloid differentiation; however, constitutive activation
of the Wnt pathway by a retrovirally expressed mutant b-cate-
nin in CD34+ HPCs induces cell proliferation without myelo-
monocytic differentiation even in myeloid-oriented culture.
Wnt pathway components such as Wnt1, Wnt2B, and LEF1
mRNA are overexpressed in CD34+ leukemic blast cells from
AML patients, and TCF ⁄LEF transcription activities are
increased in CD34+ leukemic cells.(13) Acute myelogenous leu-
kemia is frequently associated with somatic mutations of fms-
like tyrosine kinase 3 consisting of internal tandem duplica-
tions, which occur in approximately 30% of patients with
AML and are associated with poor prognosis.(14,15) This muta-
tion induces high b-catenin protein levels and enhances TCF
⁄LEF-dependent transcriptional activity.(16) Moreover, b-cate-
nin and TCF ⁄LEF target genes such as c-myc and cyclin D1
are overexpressed in U937 cells expressing AML-associated
transcription products such as AML1-ETO, PML-RARa, and
PLZF-RARa.(17) The canonical Wnt pathway plays a role in
leukemogenesis.
Aberrant Wnt pathway activation is associated with the
pathogenesis of lymphoid malignancies. In normal hematopoi-
esis, LEF1 plays a crucial role in the development of B and
T cells.(18,19) LEF1 is overexpressed in lymphoid malignan-
cies including ALL,(20) CLL,(21) and malignant lymphoma.(22)
In B-cell progenitor ALL cell lines and primary B-ALL cells,
the Wnt ⁄b-catenin pathway is activated by the overexpression
of Wnt genes including WNT2B, WNT5A, WNT10B, and
WNT16B, and also the Wnt receptors FZD7 and FZD8.
Wnt3A stimulates the proliferation and survival of these
cells.(23) Furthermore, overexpression of LEF-1 mRNA
reveals a predictor of poor prognosis in patients with adult
B-precursor ALL.(20) These observations indicate that the
canonical Wnt signaling pathway plays a role in the patho-
genesis of B-ALL.
B-cell CLL is characterized by the accumulation of mature
and functionally incompetent B cells. The canonical Wnt path-
way-related genes and proteins are overexpressed in CLL and
b-catenin signaling inhibition decreases cell survival.(24,25)
Pharmacological inhibition of GSK-3b promotes b-catenin-
mediated transcription, and Wnt ⁄b-catenin inhibition by an
analog of a non-steroidal anti-inflammatory drug induces apop-
tosis of CLL cells.(25) Multiple myeloma is a neoplastic disor-
der of plasma cells. Multiple myeloma cell lines and primary
MM cells overexpress b-catenin,(26,27) and soluble Wnt pro-
teins increase b-catenin protein levels and b-catenin ⁄TCF tran-
scription.(26,28) Therefore, the canonical Wnt pathway is
considered a therapeutic target for the treatment of
MM.(26,27,29,30) In addition to B cell malignancies, the Wnt ⁄b-
catenin signaling cascade is required for thymopoiesis.(31,32) b-
Catenin stabilization inhibits the developmental transition from
double-positive to single-positive thymocytes and induces
T-ALL independently of Notch signaling.(33)
Wnt ⁄ b-catenin Pathway in Leukemic Stem Cells
The Wnt pathway plays an important role in the maintenance
of adult somatic stem cells.(34) The R-spondin ⁄ leucine-rich
repeat containing, G-protein-coupled receptor 5 signaling
maintains intestinal stem cells through the Wnt pathway.(35)
The activation of the Wnt ⁄b-catenin pathway by orphan
nuclear receptor tailless stimulates the proliferation and the
self-renewality of neural stem cells.(36) In addition to the main-
tenance of these somatic stem cells, the Wnt ⁄b-catenin path-
way is essential for the maintenance of HSCs, as discussed in
the previous section.
Fig. 1. Wnt ⁄ b-catenin signaling pathway. In the
absence of Wnt, in the “Wnt signal-off” state (left
panel), the b-catenin destruction complex is
polyubiquitinated by b-transducin repeat-
containing protein (b-TrCP) and phosphorylated b-
catenin (b-Cat) is then degraded by the
proteasome. In the presence of Wnt, in the “Wnt
signal-on” state (right panel), phosphorylation of b-
catenin is suppressed and b-catenin escapes from
degradation. Free cytoplasmic b-catenin
translocates to the nucleus and forms a complex
with T-cell factor (TCF) ⁄ lymphocyte enhancer factor
(LEF). The b-catenin ⁄ TCF complex activates the
transcription of target genes including cyclin D1
and c-myc. APC, adenomatous polyposis coli; BCL9,
B-cell chronic leukocytic leukemia/lymphoma 9;
CBP, c-AMP response element binding protein-
binding protein; CK1a, casein kinase 1a; Dkk,
Dickkopf; Dvl, dishevelled; Fz, Frizzled; HDAC,
histone deacetylase; LRP5 ⁄ 6, lipoprotein receptor-
related protein 5 ⁄ 6; P, phosphorylation; PYG,
pygopus; SFRP, soluble frizzled-related protein; Ub,
ubiquitination; WIF-1, Wnt inhibitory factor-1.
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The Wnt ⁄b-catenin pathway also contributes to the develop-
ment of LSCs. Wang et al.(37) produced leukemias in mice by
overexpressing HOXA9 and a HOX coactivator, MEIS1a, or
the MLL-AF9 fusion protein in HSCs and non-self-renewal
GMPs. In the absence of the activated Wnt pathway, AML
developed in transformed HSC-transplanted mice; however, in
the presence of the constitutively activated b-catenin protein,
the transformed GMPs induced AML and reduced the survival
of transplanted mice, indicating that the activation of Wnt ⁄b-
catenin signaling produces LSCs from either HSCs or more
differentiated GMPs.
Chronic myelogenous leukemia is a clonal myeloprolifera-
tive disorder of HSC origin caused by the constitutive activa-
tion of the BCR–ABL 1 tyrosine kinase. The development of
TKIs such as imatinib, dasatinib, and bosutinib has dramati-
cally improved the prognosis of CML patients.(38,39) However,
TKIs cannot eradicate CML stem cells because CML stem
cells are insensitive to TKIs.(40–42) Activation of the Wnt ⁄b-
catenin pathway was detected in samples from patients with
CML in blastic crisis. Additionally, appropriate activation of
the Wnt signaling pathway in GMPs confers self-renewal
capacity, suggesting that aberrant Wnt pathway activation
results in the acquisition of CML stem cell features by leuke-
mic GMPs in the blastic phase of CML.(42) These observations
were confirmed in murine studies. Mice transplanted with
BCR–ABL-transfected HSCs from b-catenin knockout mice
show a significant delay in the onset of CML, and loss of b-
catenin impairs the self-renewal capacity of CML stem cells.(7)
Taken together, these findings indicate that the Wnt ⁄b-catenin
pathway is involved in the maintenance of LSCs and is there-
fore a promising target for the development of therapies
against LSCs, as reviewed previously.(43)
Epigenetic Dysregulation of the Wnt ⁄ b-catenin Pathway in
Hematological Malignancies
Epigenetic abnormalities play an important role in carcinogen-
esis. DNA methylation abnormalities have been investigated in
relation to the canonical Wnt pathway in hematological malig-
nancies. DNA methylation usually occurs in the region of
“CpG islands” and involves the addition of a methyl group to
the carbon-5 position of the cytosine ring in the CpG dinucleo-
tide catalyzed by DNA methyltransferase. CpG island methyla-
tion is associated with gene silencing and aberrant CpG island
methylation (hypermethylation) is observed in many cancers.
Abnormal methylation of Wnt antagonists including SFRPs,
DKKs, and WIF-1 is detected in several types of hematological
malignancies,(44–48) and is associated with decreased survival
in patients with ALL and AML.(45,46) Moreover, hypermethyla-
tion of Wnt inhibitors is associated with genetic aberrations
including class II mutations such as AML1 ⁄RUNX1, MLL
⁄PTD, PML ⁄RARa, and ASXL1.(44)
Dysregulation of the Wnt ⁄ b-catenin Pathway Through the
Bone Marrow Microenvironment
The BM microenvironment supports hematopoiesis, and the
BM niche regulates the proliferation and differentiation of
HSCs and hematopoietic progenitors through various mecha-
nisms (cell-to-cell contact or humoral factors). Among these
mechanisms, canonical Wnt ⁄b-catenin signaling in BM mesen-
chymal cells is dispensable for hematopoiesis.(49–51) Similar to
normal hematopoiesis, the BM microenvironment has a signifi-
cant effect on Wnt ⁄b-catenin signaling. In a coculture system
using human BM stromal cells and CML cells, adhesion of
CML cells to MSCs through N-cadherin induced b-catenin
nuclear translocation and transcriptional activities, resulting in
the protection of CML CD34+ ⁄CD38 progenitors from TKI
treatment.(52) Acute lymphoblastic leukemia cell lines cocul-
tured with MSCs are also protected from the effects of anti-
cancer drugs. Mesenchymal stromal cells express Wnt ligands,
especially Wnt3 and Wnt5A, and ALL cells cocultured with
MSCs express LEF1 and cyclin-D1-binding protein 1, which
explains the resistance of ALL cells to anticancer agents. Wnt
⁄b-catenin signaling in the BM microenvironment also plays a
role in the pathogenesis of leukemias.
The BM is hypoxic, particularly at the epiphysis.(53) Normal
HSCs reside in this hypoxic epiphyseal region “niche”, and
HSCs are protected from DNA damage induced by reactive
oxygen species.(53,54) In previous studies, we showed that
CML cells engrafted in the BM survive and proliferate in the
severely hypoxic environment and these hypoxia-adapted leu-
kemic cells are resistant to TKIs and acquire stem cell-like
characters.(55,56) These cells express b-catenin at much higher
levels than CML cells cultured under normoxic conditions, and
the novel Wnt ⁄b-catenin signaling inhibitor AV-65 (discussed
later) suppresses the proliferation of these CML stem cell-like
cells.(56) These observations suggest that the Wnt ⁄b-catenin
signaling pathway plays a role in the maintenance of CML
stem cells and that inhibition of the Wnt pathway may eradi-
cate CML stem cells.
Small Molecule Inhibitors of the Wnt ⁄ b-catenin Pathway
Strategies to inhibit Wnt ⁄b-catenin signaling have been
researched for their potential in the treatment of cancers. Small
molecule compounds have been developed extensively as ther-
apeutic agents because of their ability to target intracellular
proteins.(57,58) Small molecule screening, which is critical for
the identification and development of effective compounds, is
Fig. 2. Schematic representation of protein–protein interaction-
based assay screening. b-Catenin attached onto plates was exposed to
glutathione-S-transferase (GST)-fused T-cell factor 4 (TCF4). Anti-GST
antibody and an alkaline phosphatase (AP)-conjugated secondary anti-
body were added to the plate. After the addition of compounds, dis-
ruption of the b-catenin ⁄ TCF complex was measured by the reduction
of AP signals. In addition to compounds, in silico synthesized peptides
are also used for screening. ALP, alkaline phosphatase.
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performed by three methods. The first approach is based on
protein–protein interactions. Lepourcelet et al.(59) established
an HTS method for the identification of inhibitors of b-catenin
⁄TCF complex formation. His group developed a binding assay
by attaching purified b-catenin, including the TCF binding site,
onto a plate (Fig. 2). Approximately 7000 purified natural
compounds were screened and six compounds were identified
as inhibitors, among which two fungal derivatives, namely
PKF115-584 and CGP049090 (Table 1), were effective antago-
nists of the b-catenin ⁄TCF complex. These compounds have
been shown to be effective against hematological malignancies
in vitro and in vivo.(26,60,61)
The second approach is cell-based reporter assay screening.
Wnt ⁄b-catenin signaling activity can be assessed using the
TOPFlash reporter that contains TCF ⁄LEF binding sites
upstream of the luciferase ORF. Luciferase activity in reporter
Table 1. Recent examples of Wnt ⁄ b-catenin inhibitors
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cells stably expressing TOPFlash indicates b-catenin ⁄TCF
transcriptional activity. This assay is used to screen small mol-
ecule libraries for inhibitors of the Wnt ⁄b-catenin signaling
pathway (Fig. 3). Huang et al.(62) identified XAV939 (Table 1)
as a Wnt ⁄b-catenin pathway inhibitor using the TOPFlash
reporter assay and showed that this synthetic compound inhib-
its tankyrase1 and tankyrase2, leading to the stabilization of
Axin and the degradation of b-catenin. Tankyrases promote
the ubiquitination of Axin, possibly through poly-ADP-ribosy-
lation. XAV939 inhibits poly-ADP-ribosylation by binding
tightly to the poly-(ADP-ribose) polymerase domain of tanky-
rases, and was shown to reduce stroma-mediated drug resis-
tance in ALL cells through this mechanism.(63) Emami
et al.(64) screened a small molecule library of 5000 compounds
using a cell-based reporter assay system and identified a small
molecule, ICG-001, based on its ability to downregulate the
expression of b-catenin ⁄TCF target genes. c-AMP response
element binding protein-binding protein is a transcriptional co-
activator that binds to the C-terminal region of b-catenin, mod-
ulating its stability through protein acetylation. ICG-001
(Table 1) binds CBP (but not p300) and competes for binding
to b-catenin, resulting in the inhibition of colon cancer cell
proliferation. Recently, this unique ICG-001 compound was
shown to eliminate drug-resistant clones in ALL(65) as well as
CML stem cell-like cells under hypoxic conditions.(66) PRI-
724 was developed as a second generation CBP ⁄b-catenin
antagonist, and the clinical trial (phase I) of PRI-724 in
advanced solid tumors was carried out (NCT01302405). The
results of this clinical trial revealed that PRI-724 has an
acceptable toxicity.(67) The following clinical trials in subjects
Fig. 4. Schematic representation of biomarker-
based screening. This assay proceeds in two steps:
(i) setting up gene signatures through b-catenin
siRNA treatment; and (ii) screening for compounds
with similar expression patterns.
Fig. 3. Schematic representation of cell-based
reporter assay screening. A dual-luciferase assay
system is used. Wnt ⁄ b-catenin signaling activity can
be assessed using the TOPFlash reporter that
contains T-cell factor (TCF) ⁄ lymphocyte enhancer
factor binding sites upstream of the luciferase ORF.
Firefly luciferase is expressed in response to b-
catenin ⁄ TCF transcriptional activity. Renilla
luciferase is constitutively expressed and used as a
control.
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with AML and CML are underway (NCT01606579). More-
over, Kida et al. and Ma et al. clearly demonstrated that ICG-
001 inhibited the CBP-associated gene transcription.(64,68)
Interestingly, the transcriptional coactivator CBP, not p300, is
essential for HSC self-renewality.(69) Considering these obser-
vations, specific CBP ⁄b-catenin inhibitors such as ICG-001
and PRI-724 can eliminate LSCs, and these compounds are
expected to cure hematological malignancies.
The third method is biomarker-based screening, which is a
new HTS method based on transcriptional profiling. Transcrip-
tional activity can correlate with the specific state of a disease.
Whole genome transcriptional profiling is costly and time con-
suming; however, transcriptional profiling using HTS is possi-
ble when the cellular state can be monitored through the
expression of selected genes. Advances in transcriptional pro-
filing techniques have improved the scale, cost, and ease of
use of this method. Biomarker-based screening focuses on spe-
cific transcriptional activities to identify compounds of interest.
In addition, transcriptional profiling enables the comparison of
results and offers good reproducibility.
Bol and Ebner(70) examined the transcriptional response of a
colon cancer cell line to b-catenin siRNA using full-genome
microarray analysis (Fig. 4), and selected nine biomarkers for
their potential as indicators of the response to cancer therapy.
To identify compounds showing a similar expression pattern to
that of the siRNA, a library of 90 000 individual compounds
was screened, resulting in the identification of AV-65, an
anthraquinone oxime compound (Table 1) capable of mimick-
ing b-catenin knockdown. The effect of AV-65 on promoting
the degradation of b-catenin and inhibiting b-catenin ⁄TCF
transcriptional activity was validated in MM cells. AV-65
induces the degradation of b-catenin by promoting b-TrCP-
mediated ubiqutination, and downregulates the expression of c-
myc, cyclin D1, and survivin, leading to the inhibition of MM
cell proliferation. Moreover, AV-65 treatment prolongs the
survival of MM-bearing mice, making it an attractive
agent against MM.(29) AV-65 inhibits the proliferation of
imatinib-resistant CML cells with the T315I mutation and
stem-like characteristics.(56) BC2059, a derivative of AV-65,
inhibited the proliferation of AML cells by disrupting the
canonical Wnt ⁄b-catenin pathway.(71)
Conclusion
Aberrant activation of canonical Wnt ⁄b-catenin signaling plays
a role in carcinogenesis and the progression of hematological
malignancies; therefore, the inhibition of Wnt ⁄b-catenin sig-
naling is an effective approach to the treatment of hematologi-
cal malignancies. Advances in screening methodology have
enabled the identification of Wnt ⁄b-catenin signaling inhibi-
tors, and the efficacy of these compounds has been established
in preclinical and clinical investigations.
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